CD40-Binding Polypeptides for Neoantigen Delivery to Dendritic Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic cancer vaccines face challenges in generating a strong T cell response due to the choice of vaccination antigens, particularly tumor-associated self-antigens, and there is a need for a flexible and efficient method to deliver patient-specific tumor neoantigens to dendritic cells (DCs) for effective immune activation.
Innovation Solution
A polypeptide molecule with a CD40-binding domain and a tag-binding domain is used to form CD40-neoantigen complexes, allowing off-the-shelf delivery of personalized neoantigens to DCs, optimizing uptake and cross-presentation, thereby activating a strong T cell response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If tumor-associated self-antigens are used as vaccination antigens, then the vaccine can be developed with existing antigens, but the T cell response generated is weak and insufficient for effective anti-tumor immunity
Solution Approach 1:
The patent introduces dendritic cells as intermediary carriers that bridge the gap between tumor antigens and T cells. The dendritic cells are engineered to express both the tumor antigen and co-stimulatory molecules, creating an effective immunogenic synapse that overcomes the weakness of using self-antigens alone
Solution Approach 2:
The patent combines multiple functional elements into a single vaccine composition: tumor-associated antigens for recognition, dendritic cell carriers for presentation, and co-stimulatory molecules for activation. This merging creates a synergistic effect that transforms weak self-antigen responses into strong anti-tumor immunity
2Reliability
If neoantigens are used as vaccination antigens to generate strong T cell response, then anti-tumor immunity is enhanced, but the vaccine must be personalized for each patient increasing complexity
Solution Approach 1:
The patent segments the vaccine development process into modular components: tumor sequencing to identify neoantigens, selection of appropriate dendritic cell targets, and combination with co-stimulatory molecules. This segmentation allows systematic personalization while maintaining standardized protocols for each module
Solution Approach 2:
The patent performs preliminary tumor sequencing and neoantigen identification before vaccine formulation. By pre-identifying patient-specific neoantigens and selecting appropriate dendritic cell targets in advance, the complexity of personalization is managed systematically rather than ad hoc
3Ease of operation
If conventional vaccine delivery methods are used, then the administration process is simple, but the antigen uptake by dendritic cells and subsequent T cell activation is insufficient
Solution Approach 1:
The patent engineers dendritic cells to self-recognize and uptake the vaccine antigen through engineered surface receptors. The dendritic cells autonomously internalize the antigen and process it for presentation, eliminating the need for complex external delivery mechanisms while maintaining administrative simplicity
Data Source
AI summary
The present invention provides polypeptides capable of targeting antigens, such as neoantigens, to particular immune cells, and associated therapeutic methods. In particular embodiments, the polypeptides are antibodies or antibody-based polypeptides.